Latest filingSep 21, 2026Most recent Form 4
ELVN
Enliven Therapeutics, Inc.
NasdaqHealthcarePharmaceutical Preparations
Insider activity for last month from 08/22 to 09/22. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$55.4M6 sells
Net open-market-$55.4M2 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period10transactions
- S · Open-market sells · dominant6 · 60%
- M · Option exercise4 · 40%
Activity by reported role
A joint filing can contribute to multiple roles10transactions
- Chief financial officer · dominant5 · 50%
- CMO5 · 50%
Distinct insiders active
Reporting-owner CIKs by month · peak Sep 2026 (2)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeCollins Helen LouiseCommon Stock · Direct
27,084Sep 17, 2026
Hohl BenjaminCommon Stock · Direct
44,018Sep 17, 2026
Collins Helen LouiseStock Option (right to buy) · Direct
106,268Sep 17, 2026
Hohl BenjaminStock Option (right to buy) · Direct
181,018Sep 17, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 22 → Sep 22
LessMore
Top insiders
By absolute net value across the selected period- HB-$243.9k
- CL-$239.4k
Recent filing activity
Most recent 10 transactions · color = transaction codeFiling detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
No filing-only signal badges matched this period.
ELVN transaction history
Filters apply within this company and selected period by defaultLatest insider transactions
Form 4 filings from last month. Click any column to sort; click it again to flip the order.
| ID | Ticker | Insider | Role | Type | Shares | Value | Code | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|
| #226954 | ELVN | Hohl Benjamin | CFO | exercise10b5-1 | 3.98k | $0 | M | 09/21 | 09/17 |
| #226953 | ELVN | Hohl Benjamin | CFO | sale10b5-1 | 289 | -$1.48M | S | 09/21 | 09/17 |
| #226952 | ELVN | Hohl Benjamin | CFO | sale10b5-1 | 2.19k | -$11.1M | S | 09/21 | 09/17 |
| #226951 | ELVN | Hohl Benjamin | CFO | sale10b5-1 | 3.53k | -$17.6M | S | 09/21 | 09/17 |
| #226950 | ELVN | Hohl Benjamin | CFO | exercise10b5-1 | 3.98k | $5.91M | M | 09/21 | 09/17 |
| #226931 | ELVN | Collins Helen Louise | CMO | exercise10b5-1 | 5.00k | $0 | M | 09/21 | 09/17 |
| #226930 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 240 | -$1.23M | S | 09/21 | 09/17 |
| #226929 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 1.84k | -$9.35M | S | 09/21 | 09/17 |
| #226928 | ELVN | Collins Helen Louise | CMO | sale10b5-1 | 2.91k | -$14.5M | S | 09/21 | 09/17 |
| #226927 | ELVN | Collins Helen Louise | CMO | exercise10b5-1 | 5.00k | $1.24M | M | 09/21 | 09/17 |
Enliven Therapeutics, Inc. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at Enliven Therapeutics, Inc.?
Hohl Benjamin, Collins Helen Louise.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Hohl Benjamin reported a sale on Sep 17, 2026 valued at $1.48M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $554,756.89. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.